• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

Ahead of ASCO, Merck Touts Another Win for Lung Cancer Drug Combo

cafead

Administrator
Staff member
  • cafead   May 23, 2018 at 10:12: AM
via This morning, Merck (NYSE: MRK) announced that a Phase 3 study called Keynote-407 has succeeded. The trial tested a combination of its immunotherapy pembrolizumab (Keytruda) and chemotherapy in 560 patients just diagnosed with advanced, squamous non-small cell lung cancer.

article source
 

<